Editas Medicine Inc
(FRA:8EM)
€
2.602
0.105 (4.16%)
Market Cap: 218.64 Mil
Enterprise Value: 10.24 Mil
PE Ratio: 0
PB Ratio: 1.35
GF Score: 46/100 Editas Medicine Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 06:15PM GMT
Release Date Price:
€22.2
(+1.83%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director
(technical difficulty)
With the next session. Thanks for joining us this afternoon. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Before we start, I just need to read the disclosure statement.
Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures, or you can pick up a copy at the registration desk.
So I'm very happy to have the team from Editas with me here. Cindy, I don't know if you want to make any opening comments. If not, we can jump right in. But...
Cynthia L. Collins
Editas Medicine, Inc. - CEO, President & Director
Yes. We can jump right in. That'd be great.
Questions & Answers
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director
Okay. Great. Great. So look, I thought maybe a good place
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot